Anti-TNR4/ CD134/ TNFRSF4 monoclonal antibody

Anti-TNR4/ CD134/ TNFRSF4 antibody for FACS & in-vivo assay

Target products collectionGo to CD134/TNFRSF4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T92124-Ab-1/ GM-Tg-hg-T92124-Ab-2Anti-Human CD134/TNFRSF4 monoclonal antibodyHuman
GM-Tg-rg-T92124-Ab-1/ GM-Tg-rg-T92124-Ab-2Anti-Rat CD134/TNFRSF4 monoclonal antibodyRat
GM-Tg-mg-T92124-Ab-1/ GM-Tg-mg-T92124-Ab-2Anti-Mouse CD134/TNFRSF4 monoclonal antibodyMouse
GM-Tg-cynog-T92124-Ab-1/ GM-Tg-cynog-T92124-Ab-2Anti-Cynomolgus/ Rhesus macaque CD134/TNFRSF4 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T92124-Ab-1/ GM-Tg-felg-T92124-Ab-2Anti-Feline CD134/TNFRSF4 monoclonal antibodyFeline
GM-Tg-cang-T92124-Ab-1/ GM-Tg-cang-T92124-Ab-2Anti-Canine CD134/TNFRSF4 monoclonal antibodyCanine
GM-Tg-bovg-T92124-Ab-1/ GM-Tg-bovg-T92124-Ab-2Anti-Bovine CD134/TNFRSF4 monoclonal antibodyBovine
GM-Tg-equg-T92124-Ab-1/ GM-Tg-equg-T92124-Ab-2Anti-Equine CD134/TNFRSF4 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T92124-Ab-1/ GM-Tg-hg-T92124-Ab-2; GM-Tg-rg-T92124-Ab-1/ GM-Tg-rg-T92124-Ab-2;
GM-Tg-mg-T92124-Ab-1/ GM-Tg-mg-T92124-Ab-2; GM-Tg-cynog-T92124-Ab-1/ GM-Tg-cynog-T92124-Ab-2;
GM-Tg-felg-T92124-Ab-1/ GM-Tg-felg-T92124-Ab-2; GM-Tg-cang-T92124-Ab-1/ GM-Tg-cang-T92124-Ab-2;
GM-Tg-bovg-T92124-Ab-1/ GM-Tg-bovg-T92124-Ab-2; GM-Tg-equg-T92124-Ab-1/ GM-Tg-equg-T92124-Ab-2
Products NameAnti-CD134/TNFRSF4 monoclonal antibody
Formatmab
Target NameCD134
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CD134 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-126Pre-Made Cudarolimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody
    BiosimilarGMP-Bios-ab-482Pre-Made Revdofilimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody
    BiosimilarGMP-Bios-ab-448Pre-Made Pogalizumab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody
    BiosimilarGMP-Bios-ab-690Pre-Made Rocatinlimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody
    BiosimilarGMP-Bios-ab-285Pre-Made Ivuxolimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody
    BiosimilarGMP-Bios-ab-628Pre-Made Vonlerolizumab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody
    BiosimilarGMP-Bios-ab-558Pre-Made Telazorlimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody
    Target AntigenProducts DevelopingMulti-species TNR4/ CD134/ TNFRSF4 VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-T92124-Ag-1tumor necrosis factor receptor superfamily, member 4 (TNFRSF4) protein
    ORF Viral VectorpGMLP003939human TNFRSF4 Lentivirus plasmid
    ORF Viral VectorvGMLP003939human TNFRSF4 Lentivirus particle
    ORF Viral VectorpGMLPm001929mouse Tnfrsf4 Lentivirus plasmid
    ORF Viral VectorvGMLPm001929mouse Tnfrsf4 Lentivirus particle


    Target information

    Target IDGM-T92124
    Target NameCD134
    Gene ID7293,22163,25572,699674,489600,493665,528782,100066167
    Gene Symbol and SynonymsACT35,CD134,IMD16,Ly-70,OX40,TNFRSF4,Txgp1,TXGP1L
    Uniprot AccessionP43489,P15725
    Uniprot Entry NameTNR4_HUMAN,TNR4_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseN/A
    Gene EnsemblENSG00000186827
    Target ClassificationCheckpoint-Immuno Oncology, GPCR

    The target: CD134, gene name: TNFRSF4, also named as ACT35, CD134, IMD16, OX40, TXGP1L. The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. Knockout studies in mice suggested that this receptor promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. The knockout studies also suggested the roles of this receptor in CD4+ T cell response, as well as in T cell-dependent B cell proliferation and differentiation. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.